## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Caution: declining volume (52% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($338.27)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Generate Investment Management Ltd Has $43.62 Million Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251231T114440 | Somewhat-Bullish | Relevance: 100%
- Generate Investment Management Ltd significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 37.7% during the third quarter, bringing its total holdings to 135,000 shares valued at $43.62 million. This move positions Elevance Health as the 10th largest holding in Generate Investment Management Ltd's portfolio. Other institutional investors have also adjusted their positions, and analysts have issued varied ratings, with a consensus "Hold" and an average target price of $396.21.

**2. Brookstone Capital Management Sells 8,259 Shares of Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251231T090609 | Somewhat-Bullish | Relevance: 100%
- Brookstone Capital Management significantly reduced its stake in Elevance Health (NYSE:ELV) by 80.2%, selling 8,259 shares but retaining 2,040 shares valued at $659,000. Elevance Health exceeded Q3 expectations with EPS of $6.03 and revenues of $50.09 billion, while also declaring a quarterly dividend of $1.71. Analysts currently maintain a "Hold" rating for the stock with an average price target of $396.21.

**3. Elevance Health (NYSE:ELV) May Have Issues Allocating Its Capital**
- Source: Yahoo! Finance Canada | 20260102T140151 | Neutral | Relevance: 100%
- Elevance Health (NYSE:ELV) shows a declining Return on Capital Employed (ROCE) over the last five years, suggesting potential issues in capital allocation despite increasing capital and revenue. While the current ROCE of 9.9% is considered low and around the healthcare industry average, the company appears to be pursuing growth at the expense of short-term returns. If this increased capital investment eventually generates higher returns, it could benefit shareholders in the long run.

**4. Ninety One UK Ltd Has $146.72 Million Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260101T135846 | Somewhat-Bullish | Relevance: 100%
- Ninety One UK Ltd increased its stake in Elevance Health, Inc. (NYSE:ELV) by 19.0% in the third quarter, bringing its total holdings to 454,075 shares valued at $146.72 million. Other institutional investors also adjusted their positions in the healthcare company. Elevance Health reported strong Q3 earnings, surpassing analyst expectations, and analysts have a consensus "Hold" rating on the stock with an average target price of $396.21.

**5. Cantor Fitzgerald Investment Advisors L.P. Makes New $1.46 Million Investment in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260101T103715 | Somewhat-Bullish | Relevance: 100%
- Cantor Fitzgerald Investment Advisors L.P. has made a new $1.46 million investment in Elevance Health, Inc. (NYSE:ELV) by acquiring 4,510 shares during the third quarter. The company has a consensus "Hold" rating from analysts with an average price target of $396.21, following mixed revisions. Elevance Health also reported strong Q3 earnings, beating expectations with $6.03 EPS and $50.09 billion in revenue, and pays a quarterly dividend of $1.71.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Volume divergence: price rising (+1.6% MRS) on declining volume (52% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 13.2 |
| Current P/E | 11.8 |
| YoY Growth | -10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 1.5% to 3.1% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >4.0% for momentum thesis). MRS_5 at 1.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 52% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.10% (CS: 80) | Neutral |
| RSI_14 | 61.7 | Neutral |
| MACD Histogram | 0.14 | Bullish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.002x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $354.25
- **Stop Loss:** $338.27 (4.5% risk)
- **Target:** $386.21 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $31,882.50
- **Portfolio %:** 31.88%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*